+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

M

Actively Recruiting

Researchers are evaluating mavorixafor, a drug being studied for people aged 12 and older who have congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders. These conditions cause low neutrophil levels and lead to recurrent or serious infections. The study aims to show if mavorixafor can improve clinical outcomes and increase neutrophil counts, while also assessing its safety and tolerability. Participants will continue their current treatment during the study, which may include therapies like granulocyte-colony stimulating factor G-CSF, immunoglobulin replacement, antibiotics, or no active treatment. They will be randomly assigned to receive either mavorixafor or a placebo orally once daily for up to 52 weeks. The study uses a quadruple-blind design to compare these groups in parallel. During the trial, participants will have regular assessments to monitor infection rates and severity, neutrophil counts, antibiotic use, oral ulcers, and fatigue levels using questionnaires. An independent committee will review infections to ensure accuracy. Safety and treatment effects will be followed throughout the 52-week treatment period. The total participation may last until the study ends in late 2027.

Age: 12Years +All GendersPhase 3
114 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of AlloNK, a non-genetically modified allogeneic natural killer NK cell therapy derived from cord blood, combined with rituximab, in people with relapsing forms of B-cell dependent rheumatologic diseases. These diseases include refractory rheumatoid arthritis, Sjgrens disease, idiopathic inflammatory myopathies, and systemic sclerosis. This open-label Phase 2a study aims to explore treatment options for patients whose conditions have not responded well to previous therapies. Participants receive AlloNK after a conditioning regimen, followed by rituximab. AlloNK is an off-the-shelf, cryopreserved NK cell therapy given in combination with rituximab. The treatment period lasts up to 104 weeks, during which participants are monitored for safety and clinical response. The study includes one treatment group receiving this combination therapy. Throughout the study, participants undergo regular assessments to evaluate safety from enrollment until the end of treatment at Week 104. Researchers measure disease-specific outcomes at Week 52, including disease activity scores for rheumatoid arthritis, Sjgrens disease activity indices, improvement scores for inflammatory myopathies, and response indices for systemic sclerosis. The study involves clinical evaluations, laboratory tests including inflammatory markers, and joint assessments to monitor treatment effects and safety over the extended period.

Age: 18Years +All GendersPhase 2
52 locations
C

Actively Recruiting

This research evaluates strategies to improve follow-up care after hospital stays for children with bronchiolitis, an acute lung condition. It focuses on comparing two different multi-component approaches intended to increase as-needed PRN follow-up prescriptions by hospital doctors and reduce unnecessary routine follow-up visits by families. The study is led by Seattle Childrens Hospital and addresses a common practice that may often result in unnecessary visits. Participants are divided into three groups those experiencing a moderate-resource implementation strategy, a high-resource implementation strategy, or no intervention as concurrent controls. The moderate-resource strategy involves educational outreach with family materials, audit and feedback on clinician performance, and clinical decision support tools. The high-resource strategy adds small-group facilitation and expert coach-led support on top of the moderate components. Concurrent control hospitals do not receive any intervention but still collect data. During the study, researchers will track adoption of PRN follow-up prescribing within 7 days after hospital discharge and monitor sustainment of these practices. Families and clinicians will be involved in decision-making supported by educational materials. The study will observe how these strategies affect follow-up visit attendance and clinical practice over time, aiming to optimize care for children hospitalized with bronchiolitis. The study runs from November 2025 to December 2029 for children aged up to 24 months.

Age: 0Months - 24MonthsAll GendersPhase Not Applicable
62 locations
Q

Actively Recruiting

Researchers are evaluating whether a quantitative HER2 assay can accurately distinguish responders from non-responders among patients with HER2-low metastatic breast cancer receiving T-Dxd. This observational study focuses on improving measurement methods for HER2 expression levels to better understand treatment response. Participants provide leftover tumor tissue from routine biopsies for analysis using quantitative immunofluorescence and RT-qPCR assays. The study measures HER2 expression via these tests and correlates results with real-world treatment responses and progression over up to 100 months following the start of T-Dxd therapy. During the study, researchers collect data on tumor HER2 levels and track objective response rates and progression-free survival. Imaging and biomarker assessments are used to evaluate measurable disease, including bone and brain metastases. Participants are monitored throughout their treatment with T-Dxd, with up to 100 months of follow-up to assess outcomes and associations with HER2 assay results.

Age: 18Years +All Genders
37 locations
P

Actively Recruiting

Researchers are studying Rina-S, a targeted antibody-drug conjugate aimed at treating participants with solid tumors that are either metastatic or cannot be removed by surgery. This Phase 12 trial evaluates Rina-Ss safety, side effects, how the body processes the drug, and its potential anti-tumor effects across various cancers including ovarian, endometrial, breast, lung, and mesothelioma. Participants receive Rina-S either alone or in combination with other cancer drugs like carboplatin, bevacizumab, pembrolizumab, or CYP3A4 inhibitors such as erythromycin or itraconazole. The study includes multiple parts, each focusing on different tumor types or combinations of therapies. Treatment continues until disease progression, unacceptable side effects, withdrawal of consent, or other specified reasons. During the study, participants undergo regular evaluations including monitoring for side effects, tumor response assessments using imaging criteria, and blood tests to measure drug levels and antibodies. Safety and effectiveness data are collected for up to about one year, with some outcomes followed for up to two years. Participants remain under medical supervision throughout the trial duration, which runs until March 2029.

Age: 18Years +All GendersPhase 1Phase 2
67 locations